• The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026
  • The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases
  • Closing is expected in the third quarter of 2026